Halozyme Therapeutics Inc (NASDAQ: HALO) is a biopharma company developing subcutaneous drug delivery platforms and oncology assets. Its ENHANZE® technology allows faster, less invasive drug administration and is licensed to major pharma companies. Halozyme offers investors recurring royalty revenue and a scalable biologics platform.